P/E spoločnosti ProMIS Neurosciences
Aká je hodnota metriky P/E spoločnosti ProMIS Neurosciences?
Hodnota metriky P/E spoločnosti ProMIS Neurosciences, Inc. je N/A
Aká je definícia metriky P/E?
P/E ratio je koeficient daný pomerom ceny akcie a príjmu spoločnosti na akciu za posledných 12 mesiacov.
The price to earnings ratio is the most widely used method for determining whether shares are accurately valued in relation to one another. But the P/E ratio does not in itself indicate whether the share is a bargain. The P/E ratio depends on the market’s perception of the risk and future growth in earnings. A company with a low P/E ratio indicates that the market perceives it as a higher risk or a lower growth or both as compared to a company with a higher price to earnings ratio. The P/E ratio of a listed company’s stock is the result of the collective perception of the market as to how risky the company is and what its earnings growth prospects are in relation to that of other companies. Investors use the P/E ratio to compare their own perception of the risk and growth of a company against the market’s collective perception of the risk and growth as reflected in the current P/E ratio.
P/E spoločností v sektore Health Care sektor na OTC v porovnaní so spoločnosťou ProMIS Neurosciences
Čomu sa venuje spoločnosť ProMIS Neurosciences?
ProMIS Neurosciences, Inc. discovers and develops precision medicine solutions for the treatment of neurodegenerative diseases, primarily Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA) in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates include PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a superoxide dismustase 1 and TAR-DNA binding protein 43 in ALS, as well as alpha synuclein in Parkinson's disease and Lewy body dementia; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils in MSA. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.
Firmy s metrikou p/e podobnou spoločnosti ProMIS Neurosciences
- Hodnota metriky P/E spoločnosti Itaconix plc je N/A
- Hodnota metriky P/E spoločnosti Arvind je N/A
- Hodnota metriky P/E spoločnosti Vista Outdoor Inc je N/A
- Hodnota metriky P/E spoločnosti Magnite Inc je N/A
- Hodnota metriky P/E spoločnosti Vocera Communication Inc je N/A
- Hodnota metriky P/E spoločnosti Bannerman Resources je N/A
- Hodnota metriky P/E spoločnosti ProMIS Neurosciences je N/A
- Hodnota metriky P/E spoločnosti Piramal Enterprises je N/A
- Hodnota metriky P/E spoločnosti V2 Retail je N/A
- Hodnota metriky P/E spoločnosti Lithium Consolidated je N/A
- Hodnota metriky P/E spoločnosti Raymond je N/A
- Hodnota metriky P/E spoločnosti Planet Ventures je N/A
- Hodnota metriky P/E spoločnosti Goodman Stapled Securities je N/A